Clinical Trial Update: Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) [Phase 3]

View source ↗

Summary

Phase 3 trial MK-3475-859 (KEYNOTE-859) evaluating pembrolizumab plus chemotherapy versus placebo plus chemotherapy in gastric/GEJ adenocarcinoma has completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma
• Gastroesophageal Junction Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Stomach Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2023-10-12